R406

目录号:S2194

仅限科研使用

R406 是一种有效的 Syk 抑制剂,无细胞试验中IC50为41 nM,对Syk抑制作用强,但是不抑制Lyn,对Flt3的作用比对Syk低5倍。R406 可诱导凋亡。Phase 1。

R406 Chemical Structure

CAS: 841290-81-1

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 2341.19 现货
RMB 1421.87 现货
RMB 7119.85 现货
大包装 有超大折扣
大剂量询单有大折扣!

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的R406发表文献89篇:

产品安全说明书

Syk抑制剂选择性比较

相关Syk产品

生物活性

产品描述 R406 是一种有效的 Syk 抑制剂,无细胞试验中IC50为41 nM,对Syk抑制作用强,但是不抑制Lyn,对Flt3的作用比对Syk低5倍。R406 可诱导凋亡。Phase 1。
特性 Rigel选择R406作为治疗风湿性关节炎的潜在领先药物。
靶点
Flt3 [1]
(Cell-free assay)
Syk [1]
(Cell-free assay)
41 nM
体外研究

R406强抑制免疫球蛋白 E (IgE)和 IgG调节的受体信号活性。R406抑制IgE抗体诱导的 LTC4 ,细胞因子和趋化因子的产生和释放, 包括TNFα, IL-8, 和GM-CSF。R406 抑制肥大细胞中T细胞Syk底物链接蛋白的激活和B细胞中B细胞链接蛋白/SLP65的磷酸化作用。R406 结合到Syk的ATP结合袋中,抑制Syk的激酶活性, R406是ATP竞争性抑制剂,Ki为30 nM。R406阻断单核细胞/巨噬细胞和中性白细胞中Syk依赖的FcR调节活性,且阻断B淋巴细胞中BCR调节活性。[1]406 明显诱导慢性淋巴细胞白血病(CCL)细胞凋亡,且阻断CCL3和CCL4 分泌。[2] R406有效抑制血小板信号,且抑制使用特殊抗体或 HIT 病患的血浆通过FcγRIIA 交叉结合形成的功能。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
AMO-1 MUTGeY5kfGmxbjDBd5NigQ>? M1zINVEh|ryP MoHSN:KhcA>? NH3WbWFz\WS3Y3XzJI1q\3KjdHnvcuKh NHPodYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1NVc3OSd-Mk[yOVE4PjF:L3G+
U266 M3XVemZ2dmO2aX;uJGF{e2G7 NIPZT2MyKM7:TR?= MnjGN:KhcA>? M{D2W5Jm\HWlZYOgcYloemG2aX;uxsA> NG\QdFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1NVc3OSd-Mk[yOVE4PjF:L3G+
Jeko-1 NVG3[2VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG0PEBp NX;HVXFRUUN3ME21MlA3QDJ4IN88US=> M375dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1O|U2Lz5{NUizOVc2PTxxYU6=
Mino MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLqOFghcA>? NXTCVnhIUUN3ME21MlcxQDV2IN88US=> M{i1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1O|U2Lz5{NUizOVc2PTxxYU6=
Jeko-1 NHO4Z3BCeG:ydH;zbZMhSXO|YYm= MkLLOeKh|ryP NVvYWWQ{OjRiaB?= Moj4bY5lfWOnczCyOU4yyqEEsdMgN{4zyqBnIHHwc5B1d3Orcx?= M1;IOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1O|U2Lz5{NUizOVc2PTxxYU6=
primary MCL MVPBdI9xfG:|aYOgRZN{[Xl? MkX6NkDDvU1? MnzPNlQhcA>? MkD2bY5kemWjc3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|wrC= NFK3PI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO4PFM4Oyd-MkWzPFg{PzN:L3G+
PBMCs NHnMeXFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX33co04OC13MDFOwG0> NInPdpczPCCq MUjEUXNQ MnfrbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? Ml:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMke4OlIoRjJ3MUK3PFYzRC:jPh?=
PBMCs NHKxTIRHfW6ldHnvckBCe3OjeR?= NIflWYM2KM7:TR?= NYezVnd{OSCq Mmj3SG1UVw>? NXLiR|l{\GWlcnXhd4V{KHSqZTDj[YxtKG2rZ4LheIlwdg>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{N{i2Nkc,OjVzMke4OlI9N2F-
CFSE-CD4+ T  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWwMlA3OjVvMTFOwG0> MnzsOEBl NYjEZYRM[myxY3vzJJBzd2yrZnXyZZRqd25ib3[gS3ZJTC2mZYLpeoVlKEOGNDxCpHQh[2WubIOgZY5lKEOGMUHiL:Kh[2WubIO= M{PJTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nke5PVgzLz5{NE[3PVk5OjxxYU6=
CFSE-CD11b+ MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqwMlA3OjVvMTFOwG0> M3T1fVgh\A>? NGPzPXNjdG:la4OgdJJwdGmoZYLheIlwdiCxZjDHWmhFNWSncnn2[YQhS0R2K9MgWEBk\WyuczDhcoQhS0RzMXKrxsBk\Wyucx?= M3XsVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nke5PVgzLz5{NE[3PVk5OjxxYU6=
HMECs Mo\RSpVv[3Srb36gRZN{[Xl? Mn;HNE0yOCEQvF2= NW\FVJN5OjBibXnu M3HUTYlvcGmkaYTzJHZGT0Zvc4TpcZVt[XSnZDDy[Yxm[XOnIH;mJG5Q NYn6bnc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlk2PDRpPkK0N|I6PTR2PD;hQi=>
AB5 NITRS|VCeG:ydH;zbZMhSXO|YYm= NHH1fZkxNTJwNTFOwG0> NFy5VXo1QCCq MXrEUXNQ M37kbYlv\HWlZYOgZZBweHSxc3nz NUjCW|hPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVg6OTFpPkKzN|k5QTFzPD;hQi=>
JB7 NInmTnVCeG:ydH;zbZMhSXO|YYm= NHXVc2gxNTJwNTFOwG0> MXe0PEBp MYfEUXNQ NX\FfHNlcW6mdXPld{BieG:ydH;zbZM> NGHXOoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5PFkyOSd-MkOzPVg6OTF:L3G+
AB5 NHTzdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LZd|AuOi53IN88US=> M3rVcVQ5KGh? MV3EUXNQ M3fROIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= NU[5SG1oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVg6OTFpPkKzN|k5QTFzPD;hQi=>
JB7 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\mRll6OC1{LkWg{txO MVK0PEBp NX\VfIx1TE2VTx?= M2TKR4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= NFTheng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5PFkyOSd-MkOzPVg6OTF:L3G+
RL M3n2O2Z2dmO2aX;uJGF{e2G7 MkfwNk42NzVizszN NGXBWJIzPC92ODDo M4XrO2ROW09? NH3yPZNqdmS3Y3XzJIEheG:2ZX70JIRm[3KnYYPlJIlvKE2PUD25JI1TVkFiZYjwdoV{e2mxbh?= NWTZOnB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlY6PjVpPkKxPVI3QTZ3PD;hQi=>
RL NGG2TpBHfW6ldHnvckBCe3OjeR?= M17H[lEwOi53IN88US=> MmjlNlQhcA>? MXnEUXNQ MUTy[YR2[2W|IITo[UBi[3SrdnH0bY9vKG:oIFHreEBidmRicEewV|ZM MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{Nkm2OUc,OjF7Mk[5OlU9N2F-
platelet  MmfySpVv[3Srb36gRZN{[Xl? NFnROlMyyqEQvH2= MlXTOUBucW5? NYjoepN1cW6qaXLpeJMhTmQQs2LJTWEudWWmaXH0[YQheGyjdHXs[ZQh[WepcnXnZZRqd25? NVPFfZF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OFg3QTRpPkKxPFQ5Pjl2PD;hQi=>
platelet  MX3GeY5kfGmxbjDBd5NigQ>? NVPabo9EOC5yNT:xM|IvPSEQvF2= NF\NN3E2KG2rbh?= NFnad4ZqdmirYnn0d{B1cGVic3nncoFtcW6pIH3lZ4hidmm|bYOg[I94dnO2cnXhcUBw\iCIY98zVmlKSQ>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh2OE[5OEc,OjF6NEi2PVQ9N2F-
DoHH2 MX3BdI9xfG:|aYOgRZN{[Xl? M3zPPVAwOy9zMDFOwG0> NWHnc|EyPDhiaB?= M3rrVYlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7 M3Tab|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEe1OFA5Lz5{MEi3OVQxQDxxYU6=
Jeko-1  MmHaRZBweHSxc3nzJGF{e2G7 Mkm5NE8{NzFyIN88US=> MlPGOFghcA>? MnXLbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHl? M2i4RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEe1OFA5Lz5{MEi3OVQxQDxxYU6=
Raji  M3X5NGFxd3C2b4Ppd{BCe3OjeR?= MYGwM|MwOTBizszN NEewUmo1QCCq NEK0[IxqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueR?= NYe4[XM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O|U1ODhpPkKwPFc2PDB6PD;hQi=>
DHL4 NWTDTIc6SXCxcITvd4l{KEG|c3H5 M1rqeVAwOS92IN88US=> NEHKcnc6PiCq NGrQbHhqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 M1jYOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
LY7 MkH1RZBweHSxc3nzJGF{e2G7 NHPDPW4xNzFxNDFOwG0> MWK5OkBp NVjuSnZ5cW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY3 MlnORZBweHSxc3nzJGF{e2G7 M3;sRVAwOS92IN88US=> MXK5OkBp MVrpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NGHET2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
DHL6 Mn7xRZBweHSxc3nzJGF{e2G7 M2PZbVAwOS92IN88US=> NV\XdmpbQTZiaB?= MUTpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 M4rYd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
LY10 MULBdI9xfG:|aYOgRZN{[Xl? M4OyUlAwOS92IN88US=> M4j3Vlk3KGh? MYjpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 Mk\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
DHL10 MV7BdI9xfG:|aYOgRZN{[Xl? MVywM|EwPCEQvF2= NF;jb|k6PiCq NH3jRoFqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NV7DdWxlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
Wsu-NHL NUH4ZXJkSXCxcITvd4l{KEG|c3H5 NGO2epcxNzFxNDFOwG0> M1Twc|k3KGh? MofYbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NUPaToxRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
LY18 NXHRfmtySXCxcITvd4l{KEG|c3H5 NVy2VGJvOC9zL{Sg{txO M{\wZ|k3KGh? NF7TO5hqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 M{T6O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
LY1 NU\5V5VGSXCxcITvd4l{KEG|c3H5 NID2U2gxNzFxNDFOwG0> M3K2TVk3KGh? NUi3XHBGcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> M1LJNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL8 MXzBdI9xfG:|aYOgRZN{[Xl? NFzDPGUxNzFxNDFOwG0> NHLZcms6PiCq NILheohqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NF7acVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
DHL4 MWrBdI9xfG:|aYOgRZN{[Xl? MmfqOEDPxE1? NXzRd2R{QTZiaB?= NY[2cYhDcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmeyB7IHHu[EA{NCCkdYSgco91KGOjc4Dhd4UhQA>? M3PCOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL6 MoW1RZBweHSxc3nzJGF{e2G7 NIPCfVM1KM7:TR?= M4nBXlk3KGh? MVrpcoR2[2W|IHPs[YF3[WenIH;mJINie3Cjc3XzJFkh[W6mIEOsJIJ2fCCwb4SgZ4F{eGG|ZTC4 MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY3 MXXBdI9xfG:|aYOgRZN{[Xl? M2TifFQh|ryP NH\GVYw6PiCq MlrobY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{A6KGGwZDCzMEBjfXRibn;0JINie3Cjc3WgPC=> NFXvd3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
LY7 MnLPRZBweHSxc3nzJGF{e2G7 M1rS[lQh|ryP NInOfXQ6PiCq NH7DVYVqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{KDliYX7kJFMtKGK3dDDuc5Qh[2G|cHHz[UA5 NF[1Tms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
DHL4 NUT4Um1CTnWwY4Tpc44hSXO|YYm= NHf3[Xo1KM7:TR?= NVXESVBxOTZiaB?= M3K2NolvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u NH3IUVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
LY7 MoDNSpVv[3Srb36gRZN{[Xl? MnHzOEDPxE1? NWjCZXV{OTZiaB?= M4TBUYlvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u MnTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY3 NYGxZ|NyTnWwY4Tpc44hSXO|YYm= MVi0JO69VQ>? M1PxcFE3KGh? M{TtUYlvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
DHL6 NFz0ZVBHfW6ldHnvckBCe3OjeR?= M1zIWFQh|ryP NVzscWk3OTZiaB?= NILUVFJqdmirYnn0d{B1d26rYzDCUG5MKHS7cn;zbY5mKHCqb4PwbI9zgWyjdHnvci=> MkXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY10 M3HJdGZ2dmO2aX;uJGF{e2G7 NVLkN4d7PCEQvF2= NVPUeoRDOTZiaB?= MVPpcohq[mm2czD0c45q[yCETF7LJJR6em:|aX7lJJBpd3OyaH;yfYxifGmxbh?= NYnXO21NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
Wsu-NHL NVu5V|dETnWwY4Tpc44hSXO|YYm= MXS0JO69VQ>? NX\W[|hmOTZiaB?= M2HjdIlvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u NYjYbFdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
LY18 NG\nS|BHfW6ldHnvckBCe3OjeR?= NFXvTlM1KM7:TR?= MnS2NVYhcA>? NFznOHVqdmirYnn0d{B1d26rYzDCUG5MKHS7cn;zbY5mKHCqb4PwbI9zgWyjdHnvci=> NXfuSIRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
MV411 NFPnW3NHfW6ldHnvckBie3OjeR?= MVK3NkBpenN? NWW1PWxOUW6qaXLpeIlwdiCxZjDGcJQ{KGmwIHj1cYFvKE2YNEGxJINmdGy|IHHzd4V{e2WmIHHzJIF{e2W|c3XkJIF{KHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGmwY4XiZZRqd25iYomgd5Bm[3S{b4Doc5RwdWW2comsJGVEPTB;MD6wNe69VS5? NX\mbopoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O|k2OTRpPkK0O|c6PTF2PD;hQi=>
TF1 NH3SXHJHfW6ldHnvckBie3OjeR?= M13CXlEhcHJ? M37RbWlvcGmkaYTpc44hd2ZiSnHrNkBqdiCncon0bJJweG:rZYTpck1{fGmvdXzheIVlKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCjc4Pld5Nm\CCjczDwbI9{eGixLWP0ZZQ2KGGodHXyJFEhcHJiaX7jeYJifGmxbjygSWM2OD1yLkCxN:69VS5? NIjPVm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe3PVUyPCd-MkS3O|k2OTR:L3G+
neutrophils MkH2SpVv[3Srb36gZZN{[Xl? MkLXTY5pcWKrdHnvckBw\iCVWVugbY4hcHWvYX6gcoV2fHKxcHjpcJMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIF\j[ZB{cWyxbmKxM2Zk\2GvbXHSMY1m\GmjdHXkJJNq\26jbHnu[{Bz\XOyb37z[ZMtKEWFNUC9NE4xOzQQvF2u NHv1TZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK1O|IyOyd-MkKyOVczOTN:L3G+
SK-M-MC M1T3O2Z2dmO2aX;uJIF{e2G7 MX6xJIhz NVTjPGFpUW6qaXLpeIlwdiCxZjDS[ZQhcW5iaIXtZY4hW0tvTT3NR{Bk\WyuczDhd5Nme3OnZDDhd{Bie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTpc44h[W[2ZYKgNUBpeiCrbnP1ZoF1cW:wLDDFR|UxRTBwMEO2{txONg>? M1TEUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{e5OVE1Lz5{NEe3PVUyPDxxYU6=
mast cells MYHGeY5kfGmxbjDhd5NigQ>? MkTzNUBpeg>? Ml;jTY5pcWKrdHnvckBw\iClS3n0JIlvKHO2ZX2gZ4VtdCCoYXP0c5Iue3SrbYXsZZRm\CCkb37lJI1ienKxdzDk[ZJqfmWmIH3veZNmKG2jc4SgZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1cW:wIHHmeIVzKDFiaIKgbY5kfWKjdHnvckwhTUN3ME2wMlA1Ps7:TT6= M3izZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{e5OVE1Lz5{NEe3PVUyPDxxYU6=
B-cells M{TWbmZ2dmO2aX;uJIF{e2G7 NF\DWphKdmirYnn0bY9vKG:oIGPZT{BqdiCqdX3hckBDNWOnbHzzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCIY3Xwd4ltd26UMT;GZ4didW2jUj3t[YRq[XSnZDDzbYdv[WyrbnegdoV{eG:wc3XzMEBGSzVyPUCuNFQ5|ryPLh?= M2j5e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkW3NlE{Lz5{MkK1O|IyOzxxYU6=
Ramos MYTGeY5kfGmxbjDhd5NigQ>? NXnEVIpDUW6qaXLpeIlwdiCxZjDTfYshcW5iYX70bYh2dWGwIFnnUU1{fGmvdXzheIVlKGi3bXHuJHJidW:|IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJGJEWi2vZXTpZZRm\CCETF7LJJBpd3OyaH;yfYxifGmxbjDifUBk\WyudXzhdkBie3OjeTygSWM2OD1yLkC1N:69VS5? MlHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5N{m1NVQoRjJ2N{e5OVE1RC:jPh?=
mesangial cells M3HUNWZ2dmO2aX;uJIF{e2G7 Mon0TY5pcWKrdHnvckBw\iCVWVugbY4h[3WudIXy[YQhcHWvYX6gcYV{[W6paXHsJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCIY3Xwd4ltd26UMT;GZ4didW2jUj3t[YRq[XSnZDDzbYdv[WyrbnegdoV{eG:wc3XzMEBGSzVyPUCuNFU3|ryPLh?= NW\vU|MyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVczOTNpPkKyNlU4OjF|PD;hQi=>
SK-N-SH NITmcJdHfW6ldHnvckBie3OjeR?= M4\DV2lvcGmkaYTpc44hd2ZiUnX0JIlvKGi3bXHuJHNMNU5vU1igZ4VtdHNuIFXDOVA:OC5yON88UU4> NW\NNVloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVczOTNpPkKyNlU4OjF|PD;hQi=>
mouse bone marrow cells NIPJTnVHfW6ldHnvckBie3OjeR?= MmX4TY5pcWKrdHnvckBw\iCLTEOg[IVx\W6mZX70JJBzd2yrZnXyZZRqd25iaX6gR|U4N0JzNjDtc5V{\SCkb37lJI1ienKxdzDj[YxteyC3c3nu[{BcO0ifdHj5cYllcW6nIHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwQVAvOTR5zszNMi=> NX7tWoNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY5ODZpPkK0O|I3QDB4PD;hQi=>
B-cells NV\YdXFpTnWwY4Tpc44h[XO|YYm= MUKxJIhz NGHibZpKdmirYnn0bY9vKG:oIGP5b{BqdiCjbIDoZWloVS2|dHnteYxifGWmIHj1cYFvKEJiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDFiaIKgbY5kfWKjdHnvckBjgSCobH;3JIN6fG:vZYTyfUwhTUN3ME2wMlE2Oc7:TT6= NUjiT5lxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O|k2OTRpPkK0O|c6PTF2PD;hQi=>
THP1 MW\GeY5kfGmxbjDhd5NigQ>? M3rneGlvcGmkaYTpc44hd2ZiU2nLJIlvKGi3bXHuJHRJWDFiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGZk\XC|aXzvcnIyN0[lZ3HtcYFTNW2nZHnheIVlKHOrZ37hcIlv\yC{ZYPwc45{\XNuIFXDOVA:OC5zN{JOwG0v NXf0Z4tPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVczOTNpPkKyNlU4OjF|PD;hQi=>
B-cells NUTtOYVnTnWwY4Tpc44h[XO|YYm= M4f6flEhcHJ? Ml:1TY5pcWKrdHnvckBw\iCVeXugbY4h[WyyaHHJ[20ue3SrbYXsZZRm\CCqdX3hckBDKGOnbHzzJIF{e2W|c3XkJIF{KEOGOE[g[ZhxemW|c3nvckBi\nSncjCxJIhzKGmwY4XiZZRqd25iYomg[oxwfyCleYTvcYV1enluIFXDOVA:OC5|M{ZOwG0v NYDVUmJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O|k2OTRpPkK0O|c6PTF2PD;hQi=>
Ramos MVvGeY5kfGmxbjDhd5NigQ>? NYjOXVJWUW6qaXLpeIlwdiCxZjDTfYshcW5iYX70bUBK\01vc4TpcZVt[XSnZDDoeY1idiCUYX3vd{Bk\WyuczDhd5Nme3OnZDDhd{BDVE6NIIDoc5NxcG:{eXzheIlwdiCkeTDj[YxtfWyjcjDhd5NigSxiSVO1NF0xNjR3N988UU4> NWjQVWYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY5ODZpPkK0O|I3QDB4PD;hQi=>
Rec1 NFLidVRHfW6ldHnvckBie3OjeR?= NIjjRngzNjVidV2= Mk\0OkBpenN? NILqXoRKdmirYnn0bY9vKG:oIFLUT{BxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gVoVkOSClZXzsd{BifCB{LkWgeW0hcW6ldXLheIVlKG[xcjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIH3leIhw\A>? M3jUR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKyPFc4Lz5{NUKyNlg4PzxxYU6=
Rec1 MYXGeY5kfGmxbjDhd5NigQ>? MkPUNk42KHWP MUS2JIhzew>? NHzvc2JKdmirYnn0bY9vKG:oIGP5b{BxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gVoVkOSClZXzsd{BifCB{LkWgeW0hcW6ldXLheIVlKG[xcjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIH3leIhw\A>? MnrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkK4O|coRjJ3MkKyPFc4RC:jPh?=
Rec1 NYXR[lZVTnWwY4Tpc44h[XO|YYm= NEfZ[JozNjVidV2= MUG2JIhzew>? M1fkVmlvcGmkaYTpc44hd2ZiTInuJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDS[YMyKGOnbHzzJIF1KDJwNTD1UUBqdmO3YnH0[YQh\m:{IE[gbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdibXX0bI9l MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O|c9N2F-
SJ-GBM2 MX;xTHRUKGG|c3H5 NUPEfGpNeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 NFruXGVyUFSVIHHzd4F6 M{TpW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MoOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC Mn24dWhVWyCjc4PhfS=> NUTFVIc3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> NVfBPWZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 NVzWRnN{eUiWUzDhd5NigQ>? M3HBUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 MVnxTHRUKGG|c3H5 NWjTUYVreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> NFPYNWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MlrydWhVWyCjc4PhfS=> MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| NF3CS|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NWm1NGp5eUiWUzDhd5NigQ>? NUTMNJN5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= M2XSZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Assay
Methods Test Index PMID
Western blot p-RPS6 / T-RPS6 / p-4E-BP1 / T-4E-BP1 p-MEK / T-MEK / p-ERK / T-ERK p-c-RAF / T-c-RAF p-AKT / T-AKT / p-mTOR / T-mTOR 23535559
Growth inhibition assay Cell viability (U87, U251 cells) Cell viability (GSC lines) 31043589
体内研究 在已经预防处理的鼠内进行阳性Arthus 反应,5 mg/kg R406诱导鼠皮肤病变达到86%。R406作用于抗体诱导的关节炎鼠模型,也有效抑制炎症。[1] 自身免疫反应时,R406不会影响巨噬细胞和嗜中性粒细胞的功能,免疫毒性为最低水平。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[1]
  • Animal Models: 在C57BL/6鼠中腹腔注射150 μL 取自成年K/BxN鼠的混合血清诱导产生关节炎。
  • Dosages: 1 或5 mg/kg
  • Administration: 口服处理

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5%dmso+95%cornoil

6mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 628.63
化学式

C22H23FN6O5.C6H6O3S

CAS号 841290-81-1
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01725230 Completed Drug: Fostamatinib|Drug: Rosuvastatin|Drug: Simvastatin Rheumatoid Arthritis AstraZeneca November 2012 Phase 1
NCT01598571 Completed Drug: Fostamatinib Healthy AstraZeneca May 2012 Phase 1
NCT01387308 Completed Drug: Fostamatinib Healthy AstraZeneca August 2011 Phase 1
NCT01355354 Completed Drug: Digoxin|Drug: Fostamatinib Healthy Volunteers|Rheumatoid Arthritis AstraZeneca June 2011 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
What’s the difference between S1533 and S2194?

回答:
S1533 and S2194 are two different forms of R406. S1533 is the free base form, containing only R406 molecule without a acid added to it. S2194 has an additional C6H6O3S acid on it which makes the molecule a salt form. The free base and salt forms have same biology activities. Free base has a lower molecular weight and salt form has a better solubility in DMSO.